Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine Biomarkers in Treatment-Resistant Depression
NCT03573349Phase 1Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Jan 2019
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ketamine in treatment-resistant depression (TRD), sponsored by Mayo Clinic. Primary endpoints: Percent change in anterior cingulate cortex (ACC) GABA and Glutamate at 24 hours, Remission based on Montgomery Asberg Depression Rating Scale (MADRS <=9) at 24 hours and 1 more. Started Jan 2019; status: active, not recruiting.
02
Drugs
ketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT03573349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03573349.